Trials / Completed
CompletedNCT03963739
Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer
Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 255 (actual)
- Sponsor
- Wake Forest University Health Sciences · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to examine how adenocarcinoma of the prostate treatment differentially affects African American men's ability to work and to describe and compare changes in work ability (as measured through self-reported global work ability item) reported by African American and white adenocarcinoma of the prostate survivors before treatment and 6 months after treatment completion.
Detailed description
This observational, longitudinal study will recruit approximately 255 patients through the Wake Forest National Cancer Institute Community Oncology Research Program (NCORP) Research Base (WF NCORP RB). The recruitment goal will be to have 160 participants who complete the interviewer-administered Structured Questionnaire at all three time points. All participants will be administered the first Structured Questionnaire prior to a prostatectomy or initiation of radiation therapy to treat adenocarcinoma of the prostate. Participants will also be administered Structured Questionnaires at three and six months after the prostatectomy or completion of radiation therapy. For most patients, the time between study enrollment and completion of participation will be approximately 6 - 10 months. Interviewer-administered Structured Questionnaires will address work ability, job characteristics, presence of symptoms associated with adenocarcinoma of the prostate treatment, and general background information.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Interview | Undergo interview |
| OTHER | Questionnaire Administration | Ancillary studies |
Timeline
- Start date
- 2019-07-19
- Primary completion
- 2025-03-25
- Completion
- 2025-03-25
- First posted
- 2019-05-28
- Last updated
- 2025-07-16
Locations
326 sites across 2 countries: United States, Guam
Source: ClinicalTrials.gov record NCT03963739. Inclusion in this directory is not an endorsement.